This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
These 3 Companies are Seeing Supercharged Sales Growth
by Derek Lewis
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
LLYPositive Net Change ETNNegative Net Change IBKRPositive Net Change
artificial-intelligence earnings finance pharmaceuticals
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
by Sundeep Ganoria
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
by Ahan Chakraborty
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
by Ekta Bagri
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
by Kinjel Shah
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
BIIBPositive Net Change JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
GSK Adds Around $5B in a Month: Here's How to Play the Stock
by Kinjel Shah
GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.
GSKNegative Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
by Abhinab Dasgupta
Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.
FASTNegative Net Change TMONegative Net Change TSCONegative Net Change ORCLNegative Net Change MTZNegative Net Change LPGNegative Net Change LITENegative Net Change NTLAPositive Net Change FSBWNegative Net Change CBRENegative Net Change PHARNegative Net Change
computers pharmaceuticals
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
by Zacks Equity Research
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
SNYNegative Net Change ADPTNegative Net Change AKRONegative Net Change ALGSPositive Net Change
pharmaceuticals
Pfizer's Golden Cross Signals Strength: How to Play the Stock
by Kinjel Shah
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
by Ahan Chakraborty
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
by Zacks Equity Research
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
ALNYPositive Net Change RHHBYPositive Net Change CRMDNegative Net Change KNSAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
by Zacks Equity Research
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
BIIBPositive Net Change LLYPositive Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies
by Zacks Equity Research
Zacks spotlights Eli Lilly, Oracle, Procter & Gamble, and microcap Comstock Holding, with pharma and staples facing pressure while Oracle and Comstock show momentum.
PGPositive Net Change LLYPositive Net Change ORCLNegative Net Change CHCINegative Net Change
computers construction consumer-discretionary pharmaceuticals
Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?
by Zacks Equity Research
Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.
UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change
insurance medical pharmaceuticals
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
PFEPositive Net Change MRNANegative Net Change BYDNegative Net Change NVAXPositive Net Change SCVLPositive Net Change
consumer-discretionary medical pharmaceuticals retail
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
by Zacks Equity Research
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
JNJPositive Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechs medical pharmaceuticals
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
by Zacks Equity Research
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
CRMDNegative Net Change KNSAPositive Net Change OTLKPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
by Kinjel Shah
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
JNJPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.
PGPositive Net Change LLYPositive Net Change UNPNegative Net Change CVSPositive Net Change ORCLNegative Net Change BKRNegative Net Change CHCINegative Net Change
pharmaceuticals tech-stocks
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
by Zacks Equity Research
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
by Ahan Chakraborty
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
ALNYPositive Net Change PFEPositive Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
by Zacks Equity Research
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
INOPositive Net Change CRMDNegative Net Change KNSAPositive Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?
by Kinjel Shah
Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
by Kanishka Das
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
SNYNegative Net Change AZNPositive Net Change MRKPositive Net Change
pharmaceuticals
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
by Sundeep Ganoria
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
VRTXPositive Net Change BEAMPositive Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy medical pharmaceuticals